Mobilized peripheral blood grafts include more than hematopoietic stem cells: The immunological perspective

F. Saraceni, N. Shem-Tov, A. Olivieri, A. Nagler

Research output: Contribution to journalArticlepeer-review


Although stem cell mobilization has been performed for more than 20 years, little is known about the effects of mobilizing agents on apheresis composition and the impact of graft cell subsets on patients' outcome. With the increasing use of plerixafor and the inclusion of poor mobilizers in autologous transplant procedures, new parameters other than CD34 + stem cell dose are emerging; plerixafor seems to mobilize more primitive CD34 +/CD38-stem cells compared with G-CSF, but their correlation with stable hematopoietic engraftment is still obscure. Immune recovery is as crucial as hematopoietic reconstitution, and higher T and natural killer cells infused within the graft have been correlated with better outcome in autologous transplant; recent studies showed increased mobilization of immune effectors with plerixafor compared with G-CSF, but further data are needed to clarify the clinical impact of these findings. In the allogeneic setting, much evidence suggests that mobilized T-cell alloreactivity is tempered by G-CSF, probably with the mediation of dendritic cells, even though no clear correlation with GVL and GVHD has been found. Plerixafor is not approved in healthy donors yet; early data suggest it might mobilize a GVHD protective balance of immune effectors, but further studies are needed to define its role in allogeneic transplant.

Original languageEnglish
Pages (from-to)886-891
Number of pages6
JournalBone Marrow Transplantation
Issue number7
Publication statusPublished - Jul 3 2015

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Mobilized peripheral blood grafts include more than hematopoietic stem cells: The immunological perspective'. Together they form a unique fingerprint.

Cite this